Should we vaccinate the better seroconverters or the most vulnerable? Game changing insights for COVID-19 vaccine prioritization policies

Egyptian Pediatric Association Gazette

Table 1 Seroconversion testing granted emergency authorization by the WHO (reference in text [4,5,6])

o	Trade name	Type	Dosage interval	Least interval for antibody testing after vaccination^a
mRNA-1273	Moderna	mRNA-based	2 doses, 28 days apart	14 days after 2nd dose
BNT162b2	Pfizer/BionTech	mRNA-based	2 doses, 21 days apart	7 days after 2nd dose
Ad26.COV2.S	Janssen (Johnson&Johnson)	Non-replicating viral vector	1 dose or 2 doses 56 days apart	14 days after 2nd dose
AZD1222	Oxford/AstraZeneca	Non-replicating viral vector	2 doses, 28 days apart	14 days after 2nd dose
BBIBP-CorV (Vero Cells)	Sinopharm (Beijing)	Inactivated	2 doses with 2–4 weeks interval between	14 days after 2nd dose
CoronaVac	Sinovac	Inactivated	2 doses with 2–4 weeks interval between	14 days after 2nd dose

Ad adenovirus, AZ Astrazeneca, BBIBP-CorV Beijing Institute of Biological Products, Sinopharm corona virus vaccine, BNT Biontech, CoV coronaviridae, COVID-19 coronavirus disease 2019, mRNA messenger ribonucleic acid, SARS severe acute respiratory syndrome, WHO World Health Organization
^aStandard antibody test: total immunoglobulin levels to the receptor-binding domain of the SARS-CoV-2 spike protein were measured with an anti–SARS-CoV-2 S enzyme immunoassay